Therefore, our results suggest that ipragliflozin does not act directly on the normal liver, but inhibits the development of NASH by suppressing SGLT2 in the kidney and SGLT1 in the small intestine. This evidence concerns the gene SLC5A1 and metabolic dysfunction-associated steatohepatitis.